# Revolution Medicines

Type: Company (RVMD)

Source: GetYourBrief — https://getyourbrief.com/entity/revolution-medicines
Canonical HTML page: https://getyourbrief.com/entity/revolution-medicines

## Timeline

- **2026-08-05**: Moderna flu vaccine PDUFA date — FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
- **2025-12**: Axsome full-year 2025 results — Annual revenue more than doubles to $617.1 million, with Auvelity net product revenue up 68% year over year.
- **2025-06**: Revolution Medicines mid-2025 data readout — RMC-6236 shows nearly 90% tumor response in an early-phase pancreatic cancer study, driving stock surge.

## Recent coverage (5 stories, network-wide)

### Axsome Revenue Doubles to $617M; 3 Biotechs Returned 230% vs. S&P 9% in H1
2026-07-07 06:57:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A trio of biotech stocks generated staggering H1 2026 returns, with Revolution Medicines leading at +230%. Axsome Therapeutics' revenue more than doubled to $617.1 million, underscoring a market rotation into catalyst-driven, high-growth healthcare plays amid macro uncertainty.
Full story: https://getfinancebrief.com/story/biotech-beats-sp500-financial-analysis

### Moderna's PDUFA Aug 5 Looms as 3 Biotechs Return Up to 230% in H1 2026
2026-07-07 06:57:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Three biotech stocks trounced the broader market in H1 2026 on powerful clinical and regulatory catalysts. Moderna's upcoming FDA decision for its flu vaccine could sustain momentum, while Revolution Medicine's 90% tumor response data and Axsome's $617M revenue underscore the sector's upside.
Full story: https://getbiobrief.com/story/biotech-outperform-moderna-pdufa-revolution-axsome

### DAFNA Capital Trims Axogen Stake by $6.5M Following 71% Stock Surge
2026-03-22 04:28:38 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately 265,456 shares during the fourth quarter of 2025, a move valued at $6.53 million. Despite the trim, the hedge fund maintains a significant $15.6 million stake in the nerve-repair specialist, which has seen its stock price climb 71% over the past year.
Full story: https://getfinancebrief.com/story/dafna-capital-axogen-trim-analysis

### DAFNA Capital Trims Axogen Stake Following 71% Rally and 20% Revenue Growth
2026-03-22 04:25:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, a move that follows a significant 71% surge in the company's stock price. Despite the trim, Axogen remains a significant holding for the fund as the company continues to see 20% revenue growth driven by its peripheral nerve repair portfolio.
Full story: https://getbiobrief.com/story/dafna-capital-trims-axogen-stake-71-surge

### DAFNA Capital Trims Axogen Stake Amid 71% Stock Surge and Strong Revenue Growth
2026-03-22 04:25:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

DAFNA Capital Management reduced its position in Axogen by approximately $6.5 million during the fourth quarter of 2025, following a period of significant outperformance. Despite the trim, Axogen remains a core holding for the fund as the medical device maker continues to capitalize on its 20% revenue growth and dominant position in the peripheral nerve repair market.
Full story: https://gethealthbrief.com/story/dafna-capital-axogen-trim-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.